TD Cowen Maintains Buy on Guardant Health, Raises Price Target to $210
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $200 to $210.
TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $200 to $210.